Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124518 | 0.86 | MAPK1 (0.60) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL1459733 | 0.85 | MAPK1 (0.58) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL29084329 | 0.85 | MAPK1 (0.58) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL27490020 | 0.83 | MAPK1 (0.61) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL8942192 | 0.83 | TDP1 (0.58) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL24421736 | 0.82 | MAPK1 (0.55) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL16234984 | 0.82 | MAPK1 (0.55) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL11068120 | 0.82 | TSHR (0.59) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL14410622 | 0.82 | TDP1 (0.56) | MAPK1CES1CA1CA2TDP1 | |
| SCHEMBL29101987 | 0.82 | MAPK1 (0.55) | MAPK1CES1CA1CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4265628-A2 | REVERSIBLE MODIFICATION OF NUCLEOTIDES | Pacific Biosciences of California, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11673130-B2 | Catalyst system containing a metathesis catalyst and at least one phenolic compound and a process for metathesis of nitrile-butadiene rubber (NBR) using the catalyst system | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-06-13 | — | — | US | disclosed |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11325905-B2 | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-05-10 | — | — | US | disclosed |
| WO-2021050681-A1 | REVERSIBLE MODIFICATION OF NUCLEOTIDES | Omniome, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20200148675-A1 | IMIDOPIPERIDINE COMPOUNDS AS INHIBITORS OF HUMAN POLYNUCLEOTIDE KINASE PHOSPHATASE | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2020-05-14 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| US-9452973-B2 | Modulators of the relaxin receptor 1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-09-27 | — | — | US | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2007089430-A1 | DIISOCYANATE TERMINATED MACROMER AND METHOD OF MAKING | ETHICON, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060030543-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6229022-B1 | REACTING CARBONYL COMPOUNDS WITH HYDRAZINE, ITS HYDRATE OR SALTS IN THE PRESENCE OF SULFURIC ACID AND IODINE OR AN IODINE LIBERATING COMPOUND | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030543-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC3, HDAC5 | MAPK1 2472/4885CES1 2599/4885CA1 3635/4885 |
| US-11325905-B2 | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | PNKP, PPM1A, PPM1B | MAPK1 321/4885CES1 3565/4885CA1 4676/4885 |
| US-20200148675-A1 | IMIDOPIPERIDINE COMPOUNDS AS INHIBITORS OF HUMAN POLYNUCLEOTIDE KINASE PHOSPHATASE | PNKP, PPM1A, PPM1B | MAPK1 321/4885CES1 3565/4885CA1 4676/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | MAPK1 3966/4885CES1 464/4885CA1 1330/4885 |
| US-20230148417-A1 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | WEE2, AKT1S1, WEE1 | MAPK1 95/4885CES1 903/4885CA1 4098/4885 |
| US-20080269228-A1 | HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS | HPN, SPINT2, PRSS1 | MAPK1 2577/4885CES1 20/4885CA1 767/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | MAPK1 1480/4885CES1 722/4885CA1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.